Dizal Pharmaceutical’s Zegfrovy is approved in the U.S. for locally advanced or metastatic non-small cell lung cancer. For $600 million upfront, AstraZeneca will gain global rights to advance and commercialize the asset.
AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B